Molecular pathogenesis of pulmonary arterial hypertension

Journal of Clinical Investigation

Volumn 122, Issue 12, 2012, Pages 4306-4313

  Rabinovitch, Marlene ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVIN RECEPTOR LIKE KINASE 1; ALPHA SMOOTH MUSCLE ACTIN; APELIN; APOLIPOPROTEIN E; BETA CATENIN; BONE MORPHOGENETIC PROTEIN RECEPTOR 2; ELASTASE; ESTRADIOL; HISTONE DEACETYLASE 1; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MICRORNA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PHOSPHATIDYLINOSITOL 3 KINASE; PLATELET DERIVED GROWTH FACTOR; STRESS ACTIVATED PROTEIN KINASE; SYNAPTOPHYSIN; TRANSCRIPTION FACTOR NRF2; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA1;

ADVENTITIA; CELL INTERACTION; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; CELL TRANSFORMATION; DYSPNEA; ENDOTHELIAL PROGENITOR CELL; ENZYME ACTIVITY; ESTROGEN METABOLISM; FATIGUE; GENE EXPRESSION; GENE MUTATION; GENETIC ASSOCIATION; GENETIC PREDISPOSITION; GLYCOLYSIS; HUMAN; IDIOPATHIC DISEASE; IMMUNE RESPONSE; KAPOSI SARCOMA; MOLECULAR PATHOLOGY; NONHUMAN; PERICYTE; PORTAL HYPERTENSION; PRIORITY JOURNAL; PROTEIN INDUCTION; PULMONARY HYPERTENSION; REVIEW; SCHISTOSOMIASIS; SEX DIFFERENCE; SIGNAL TRANSDUCTION;

ANIMALS; BONE MORPHOGENETIC PROTEIN RECEPTORS, TYPE II; ESTROGENS; GLYCOLYSIS; HUMANS; HYPERTENSION, PULMONARY; MUTATION; PANCREATIC ELASTASE; RECEPTORS, SEROTONIN; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; SIGNAL TRANSDUCTION; STEM CELLS;

EID: 84870523226     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI60658     Document Type: Review

References (145)

1. Simonneau G, et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol. 2009;54(1 suppl):S43-S54.
2. Rabinovitch M, et al. Pulmonary artery endothelial abnormalities in patients with congenital heart defects and pulmonary hypertension: A correlation of light with scanning electron microscopy and transmission electron microscopy. Lab Invest. 1986;55(6):632-653. (Pubitemid 17231129)
3. Rosenberg HC, Rabinovitch M. Endothelial injury and vascular reactivity in monocrotaline pulmonary hypertension. Am J Physiol. 1988;255(6 pt 2):H1484-H1491.
4. Dewachter L, et al. Angiopoietin/Tie2 pathway influences smooth muscle hyperplasia in idiopathic pulmonary hypertension. Am J Respir Crit Care Med. 2006;174(9):1025-1033. (Pubitemid 44684452)
5. Thompson K, Rabinovitch M. Exogenous leukocyte and endogenous elastases can mediate mitogenic activity in pulmonary artery smooth muscle cells by release of extracellular-matrix bound basic fibroblast growth factor. J Cell Physiol. 1996;166(3):495-505. (Pubitemid 26095476)
6. Alastalo TP, et al. Disruption of PPARgamma/beta-catenin-mediated regulation of apelin impairs BMP-induced mouse and human pulmonary arterial EC survival. J Clin Invest. 2011;121(9):3735-3746.
7. Jones PL, Cowan KN, Rabinovitch M. Tenascin-C, proliferation and subendothelial fibronectin in progressive pulmonary vascular disease. Am J Pathol. 1997;150(4):1349-1360. (Pubitemid 27152653)
8. Passman JN, et al. A sonic hedgehog signaling domain in the arterial adventitia supports resident Sca1+ smooth muscle progenitor cells. Proc Natl Acad Sci U S A. 2008;105(27):9349-9354.
9. Davie NJ, et al. Hypoxia-induced pulmonary artery adventitial remodeling and neovascularization: contribution of progenitor cells. Am J Physiol Lung Cell Mol Physiol. 2004;286(4):L668-L678. (Pubitemid 38365049)
10. Frid MG, Kale VA, Stenmark KR. Mature vascular endothelium can give rise to smooth muscle cells via endothelial-mesenchymal transdifferentiation: in vitro analysis. Circ Res. 2002;90(11):1189-1196. (Pubitemid 34786904)
11. Sakao S, Tatsumi K, Voelkel NF. Endothelial cells and pulmonary arterial hypertension: apoptosis, proliferation, interaction and transdifferentiation. Respir Res. 2009;10:95.
12. Meyrick B, Clarke SW, Symons C, Woodgate DJ, Reid L. Primary pulmonary hypertension: a case report including electronmicroscopic study. Br J Dis Chest. 1974;68(1):11-20.
13. Taraseviciene-Stewart L, Gera L, Hirth P, Voelkel NF, Tuder RM, Stewart JM. A bradykinin antagonist and a caspase inhibitor prevent severe pulmonary hypertension in a rat model. Can J Physiol Pharmacol. 2002;80(4):269-274. (Pubitemid 34451241)
14. Masri FA, et al. Hyperproliferative apoptosis-resistant endothelial cells in idiopathic pulmonary arterial hypertension. Am J Physiol Lung Cell Mol Physiol. 2007;293(3):L548-L554. (Pubitemid 47358814)
15. Xu W, et al. Increased arginase II and decreased NO synthesis in endothelial cells of patients with pulmonary arterial hypertension. FASEB J. 2004;18(14):1746-1748. (Pubitemid 39561671)
16. Xu W, et al. Alterations of cellular bioenergetics in pulmonary artery endothelial cells. Proc Natl Acad Sci U S A. 2007;104(4):1342-1347. (Pubitemid 46184006)
17. Zuckerbraun BS, et al. Nitrite potently inhibits hypoxic and inflammatory pulmonary arterial hypertension and smooth muscle proliferation via xanthine oxidoreductase-dependent nitric oxide generation. Circulation. 2010;121(1):98-109.
18. Leiper J, et al. Disruption of methylarginine metabolism impairs vascular homeostasis. Nat Med. 2007;13(2):198-203.
19. Chazova I, Loyd JE, Zhdanov VS, Newman JH, Belenkov Y, Meyrick B. Pulmonary artery adventitial changes and venous involvement in primary pulmonary hypertension. Am J Pathol. 1995;146(2):389-397.
20. Jones P, Cowan K, Rabinovitch M. Progressive pulmonary vascular disease is characterized by a proliferative response related to deposition of tenascin-C and is preceded by subendothelial accumulation of fibronectin. Am J Pathol. 1997;150(4):1349-1360.
21. Liptay MJ, et al. Neointimal macrophages colocalize with extracellular matrix gene expression in human atherosclerotic pulmonary arteries. J Clin Invest. 1993;91(2):588-594. (Pubitemid 23064144)
22. Greenway S, et al. S100A4/Mts1 produces murine pulmonary artery changes resembling plexogenic arteriopathy and is increased in human plexogenic arteriopathy. Am J Pathol. 2004;164(1):253-262. (Pubitemid 38364609)
23. Balabanian K, et al. CX(3)C chemokine fractalkine in pulmonary arterial hypertension. Am J Respir Crit Care Med. 2002;165(10):1419-1425. (Pubitemid 34522947)
24. Lane KB, et al. Heterozygous germline mutations in BMPR2, encoding a TGF-beta receptor, cause familial primary pulmonary hypertension. Nat Genet. 2000;26(1):81-84.
25. Deng Z, et al. Familial primary pulmonary hypertension (gene PPH1) is caused by mutations in the bone morphogenetic protein receptor-II gene. Am J Hum Genet. 2000;67(3):737-744. (Pubitemid 30659603)
26. Rudarakanchana N, et al. Functional analysis of bone morphogenetic protein type II receptor mutations underlying primary pulmonary hypertension. Hum Mol Genet. 2002;11(13):1517-1525. (Pubitemid 34679252)
27. Nohe A, et al. The mode of bone morphogenetic protein (BMP) receptor oligomerization determines different BMP-2 signaling pathways. J Biol Chem. 2002;277(7):5330-5338. (Pubitemid 34968578)
28. Grijelmo C, et al. Proinvasive activity of BMP-7 through SMAD4/src-independent and ERK/Rac/JNK-dependent signaling pathways in colon cancer cells. Cell Signal. 2007;19(8):1722-1732. (Pubitemid 46935428)
29. Tian Q, He XC, Hood L, Li L. Bridging the BMP and Wnt pathways by PI3 kinase/Akt and 14-3-3zeta. Cell Cycle. 2005;4(2):215-216. (Pubitemid 41365318)
30. Hamid R, Cogan JD, Hedges LK, Austin E, Phillips JA. Penetrance of pulmonary arterial hypertension is modulated by the expression of normal BMPR2 allele. Hum Mutat. 2009;30(4):649-654.
31. Roberts KE, et al. BMPR2 mutations in pulmonary arterial hypertension with congenital heart disease. Eur Respir J. 2004;24(3):371-374. (Pubitemid 39232257)
32. Humbert M, et al. BMPR2 germline mutations in pulmonary hypertension associated with fenfluramine derivatives. Eur Respir J. 2002;20(3):518-523.
33. Atkinson C, et al. Primary pulmonary hypertension is associated with reduced pulmonary vascular expression of type II bone morphogenetic protein receptor. Circulation. 2002;105(14):1672-1678. (Pubitemid 34298611)
34. Yeager ME, Halley GR, Golpon HA, Voelkel NF, Tuder RM. Microsatellite instability of endothelial cell growth and apoptosis genes within plexiform lesions in primary pulmonary hypertension. Circ Res. 2001;88(1):E2-E11.
35. Harrison RE, et al. Molecular and functional analysis identifies ALK-1 as the predominant cause of pulmonary hypertension related to hereditary haemorrhagic telangiectasia. J Med Genet. 2003; 40(12):865-871. (Pubitemid 38117534)
36. Chaouat A, et al. Endoglin germline mutation in a patient with hereditary haemorrhagic telangiectasia and dexfenfluramine associated pulmonary arterial hypertension. Thorax. 2004;59(5):446-448. (Pubitemid 38624754)
37. Jerkic M, et al. Pulmonary hypertension in adult Alk1 heterozygous mice due to oxidative stress. Cardiovasc Res. 2011;92(3):375-384.
38. Aldred MA, et al. Somatic chromosome abnormalities in the lungs of patients with pulmonary arterial hypertension. Am J Respir Crit Care Med. 2010;182(9):1153-1160.
39. Davis BN, Hilyard AC, Lagna G, Hata A. SMAD proteins control DROSHA-mediated microRNA maturation. Nature. 2008;454(7200):56-61. (Pubitemid 351931982)
40. Kang H, et al. Bone morphogenetic protein 4 promotes vascular smooth muscle contractility by activating microRNA-21 (miR-21), which down-regulates expression of family of dedicator of cytokinesis (DOCK) proteins. J Biol Chem. 2012;287(6):3976-3986.
41. Drake KM, et al. Altered MicroRNA processing in heritable pulmonary arterial hypertension: an important role for Smad-8. Am J Respir Crit Care Med. 2011;184(12):1400-1408.
42. Caruso P, et al. Dynamic changes in lung microRNA profiles during the development of pulmonary hypertension due to chronic hypoxia and monocrotaline. Arterioscler Thromb Vasc Biol. 2010;30(4):716-723.
43. Reynolds AM, et al. Bone morphogenetic protein type 2 receptor gene therapy attenuates hypoxic pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol. 2007;292(5):L1182-L1192. (Pubitemid 47084862)
44. Yang J, et al. Mutations in bone morphogenetic protein type II receptor cause dysregulation of Id gene expression in pulmonary artery smooth muscle cells: implications for familial pulmonary arterial hypertension. Circ Res. 2008;102(10):1212-1221.
45. Morrell NW, et al. Altered growth responses of pulmonary artery smooth muscle cells from patients with primary pulmonary hypertension to transforming growth factor-beta(1) and bone morphogenetic proteins. Circulation. 2001;104(7):790-795. (Pubitemid 32762677)
46. Long L, et al. Altered bone morphogenetic protein and transforming growth factor-beta signaling in rat models of pulmonary hypertension: potential for activin receptor-like kinase-5 inhibition in prevention and progression of disease. Circulation. 2009;119(4):566-576.
47. Teichert-Kuliszewska K, et al. Bone morphogenetic protein receptor-2 signaling promotes pulmonary arterial endothelial cell survival: implications for loss-of-function mutations in the pathogenesis of pulmonary hypertension. Circ Res. 2006;98(2):209-217.
48. de Jesus Perez VA, et al. Bone morphogenetic protein 2 induces pulmonary angiogenesis via Wnt-beta-catenin and Wnt-RhoA-Rac1 pathways. J Cell Biol. 2009;184(1):83-99.
49. Guignabert C, et al. Tie2-mediated loss of peroxisome proliferator-activated receptor-gamma in mice causes PDGF receptor-beta- dependent pulmonary arterial muscularization. Am J Physiol Lung Cell Mol Physiol. 2009;297(6):L1082-L1090.
50. Schopfer FJ, et al. Covalent peroxisome proliferator-activated receptor gamma adduction by nitro-fatty acids: selective ligand activity and anti-diabetic signaling actions. J Biol Chem. 2010;285(16):12321-12333.
51. Valdimarsdottir G, et al. Stimulation of Id1 expression by bone morphogenetic protein is sufficient and necessary for bone morphogenetic protein-induced activation of endothelial cells. Circulation. 2002;106(17):2263-2270. (Pubitemid 35222223)
52. Hansmann G, et al. An antiproliferative BMP-2/PPARgamma/apoE axis in human and murine SMCs and its role in pulmonary hypertension. J Clin Invest. 2008;118(5):1846-1857. (Pubitemid 351632387)
53. Merklinger SL, Jones PL, Martinez EC, Rabinovitch M. Epidermal growth factor receptor blockade mediates smooth muscle cell apoptosis and improves survival in rats with pulmonary hypertension. Circulation. 2005;112(3):423-431. (Pubitemid 41022085)
54. Jeffery TK, Upton PD, Trembath RC, Morrell NW. BMP4 inhibits proliferation and promotes myocyte differentiation of lung fibroblasts via Smad1 and JNK pathways. Am J Physiol Lung Cell Mol Physiol. 2005;288(2):L370-L378. (Pubitemid 40105376)
55. Hansmann G, et al. Pulmonary arterial hypertension is linked to insulin resistance and reversed by peroxisome proliferator-activated receptor-gamma activation. Circulation. 2007;115(10):1275-1284. (Pubitemid 46594772)
56. Takayama Y, May P, Anderson RG, Herz J. Low density lipoprotein receptor-related protein 1 (LRP1) controls endocytosis and c-CBL-mediated ubiquitination of the platelet-derived growth factor receptor beta (PDGFR beta). J Biol Chem. 2005;280(18):18504-18510. (Pubitemid 41389100)
57. Schermuly RT, et al. Reversal of experimental pulmonary hypertension by PDGF inhibition. J Clin Invest. 2005;115(10):2811-2821. (Pubitemid 41434408)
58. Ghofrani HA, Seeger W, Grimminger F. Imatinib for the treatment of pulmonary arterial hypertension. N Engl J Med. 2005;353(13):1412-1413. (Pubitemid 41362714)
59. Montani D, et al. Pulmonary arterial hypertension in patients treated by dasatinib. Circulation. 2012;125(17):2128-2137.
60. Arita Y, et al. Adipocyte-derived plasma protein adiponectin acts as a platelet-derived growth factor-BB-binding protein and regulates growth factor-induced common postreceptor signal in vascular smooth muscle cell. Circulation. 2002;105(24):2893-2898. (Pubitemid 34666104)
61. Lawrie A, et al. Evidence of a role for osteoprotegerin in the pathogenesis of pulmonary arterial hypertension. Am J Pathol. 2008;172(1):256-264.
62. Ihida-Stansbury K, et al. Tenascin-C is induced by mutated BMP type II receptors in familial forms of pulmonary arterial hypertension. Am J Physiol Lung Cell Mol Physiol. 2006;291(4):L694-L702. (Pubitemid 44498481)
63. Jones P, Crack J, Rabinovitch M. Regulation of tenascin-C, a vascular smooth muscle cell survival factor that interacts with the αvβ3 integrin to promote epidermal growth factor receptor phosphorylation and growth. J Cell Biol. 1997;139(1):279-293. (Pubitemid 27444098)
64. Lorenzen JM, et al. Osteopontin in patients with idiopathic pulmonary hypertension. Chest. 2011;139(5):1010-1017.
65. Beppu H, et al. BMPR-II heterozygous mice have mild pulmonary hypertension and an impaired pulmonary vascular remodeling response to prolonged hypoxia. Am J Physiol Lung Cell Mol Physiol. 2004;287(6):L1241-L1247. (Pubitemid 39507203)
66. West J, et al. Pulmonary hypertension in transgenic mice expressing a dominant-negative BMPRII gene in smooth muscle. Circ Res. 2004;94(8):1109-1114. (Pubitemid 38579706)
67. Long L, et al. Serotonin increases susceptibility to pulmonary hypertension in BMPR2-deficient mice. Circ Res. 2006;98(6):818-827.
68. Abenhaim L, Humbert M. Pulmonary hypertension related to drugs and toxins. Curr Opin Cardiol. 1999;14(5):437-441. (Pubitemid 29419617)
69. Dempsie Y, et al. Converging evidence in support of the serotonin hypothesis of dexfenfluramine-induced pulmonary hypertension with novel transgenic mice. Circulation. 2008;117(22):2928-2937. (Pubitemid 351787078)
70. White K, Dempsie Y, Nilsen M, Wright AF, Loughlin L, MacLean MR. The serotonin transporter, gender, and 17beta oestradiol in the development of pulmonary arterial hypertension. Cardiovasc Res. 2011;90(2):373-382.
71. Chin KM, Channick RN, Rubin LJ. Is methamphetamine use associated with idiopathic pulmonary arterial hypertension? Chest. 2006;130(6):1657-1663. (Pubitemid 46033416)
72. Dhillon NK, et al. Effect of cocaine on human immunodeficiency virus-mediated pulmonary endothelial and smooth muscle dysfunction. Am J Respir Cell Mol Biol. 2011;45(1):40-52.
73. Eddahibi S, et al. Polymorphism of the serotonin transporter gene and pulmonary hypertension in chronic obstructive pulmonary disease. Circulation. 2003;108(15):1839-1844. (Pubitemid 37296093)
74. Le Cras TD, Kim DH, Markham NE, Abman AS. Early abnormalities of pulmonary vascular development in the Fawn-Hooded rat raised at Denver's altitude. Am J Physiol Lung Cell Mol Physiol. 2000;279(2):L283-L291.
75. Eddahibi S, et al. Attenuated hypoxic pulmonary hypertension in mice lacking the 5-hydroxytryptamine transporter gene. J Clin Invest. 2000;105(11):1555-1562. (Pubitemid 30390306)
76. MacLean MR, et al. Overexpression of the 5-hydroxytryptamine transporter gene: effect on pulmonary hemodynamics and hypoxia-induced pulmonary hypertension. Circulation. 2004;109(17):2150-2155. (Pubitemid 38620226)
77. Guignabert C, et al. Transgenic mice overexpressing the 5-hydroxytryptamine transporter gene in smooth muscle develop pulmonary hypertension. Circ Res. 2006;98(10):1323-1330. (Pubitemid 43948088)
78. Liu Y, Li M, Warburton RR, Hill NS, Fanburg BL. The 5-HT transporter transactivates the PDGF{beta} receptor in pulmonary artery smooth muscle cells. FASEB J. 2007;21(11):2725-2734. (Pubitemid 47372740)
79. Simon AR, et al. 5-HT induction of c-fos gene expression requires reactive oxygen species and Rac1 and Ras GTPases. Cell Biochem Biophys. 2005;42(3):263-276. (Pubitemid 41389400)
80. Lawrie A, et al. Interdependent serotonin transporter and receptor pathways regulate S100A4/Mts1, a gene associated with pulmonary vascular disease. Circ Res. 2005;97(3):227-235. (Pubitemid 41105448)
81. Spiekerkoetter E, et al. Reactivation of gammaHV68 induces neointimal lesions in pulmonary arteries of S100A4/Mts1-overexpressing mice in association with degradation of elastin. Am J Physiol Lung Cell Mol Physiol. 2008;294(2):L276-L289. (Pubitemid 351253364)
82. Morse JH, et al. Primary pulmonary hypertension in HIV infection: an outcome determined by particular HLA class II alleles. Am J Respir Crit Care Med. 1996;153(4 pt 1):1299-1301.
83. Cool CD, et al. Expression of human herpesvirus 8 in primary pulmonary hypertension. N Engl J Med. 2003;349(12):1113-1122. (Pubitemid 37122323)
84. Durrington HJ, et al. Identification of a lysosomal pathway regulating degradation of the bone morphogenetic protein receptor type II. J Biol Chem. 2010;285(48):37641-37649.
85. Marecki JC, et al. HIV-1 Nef is associated with complex pulmonary vascular lesions in SHIV-nef-infected macaques. Am J Respir Crit Care Med. 2006;174(4):437-445. (Pubitemid 44223125)
86. Crosby A, et al. Praziquantel reverses pulmonary hypertension and vascular remodeling in murine schistosomiasis. Am J Respir Crit Care Med. 2011;184(4):467-473.
87. Graham BB, et al. Schistosomiasis-induced experimental pulmonary hypertension: role of interleukin-13 signaling. Am J Pathol. 2010;177(3):1549-1561.
88. Daley E, et al. Pulmonary arterial remodeling induced by a Th2 immune response. J Exp Med. 2008;205(2):361-372. (Pubitemid 351281602)
89. Angelini DJ, et al. Resistin-like molecule-beta in scleroderma-associated pulmonary hypertension. Am J Respir Cell Mol Biol. 2009;41(5):553-561.
90. Lundequist A, et al. Prostaglandin E(2) exerts homeostatic regulation of pulmonary vascular remodeling in allergic airway inflammation. J Immunol. 2010;184(1):433-441.
91. Song Y, Jones JE, Beppu H, Keaney JF Jr, Loscalzo J, Zhang YY. Increased susceptibility to pulmonary hypertension in heterozygous BMPR2-mutant mice. Circulation. 2005;112(4):553-562. (Pubitemid 41060796)
92. Meyrick B, Brigham K. Repeated eschrerichia coli endotocin-induced pulmonary inflammation causes chronic pulmonary hypertension in sheep. Lab Invest. 1986;55(2):164-176. (Pubitemid 16017542)
93. Stevens T, Janssen PL, Tucker AD. Acute and longterm TNF-alpha administration increases pulmonary vascular reactivity in isolated rat lungs. J Appl Physiol. 1992;73(2):708-712.
94. Taraseviciene-Stewart L, et al. Absence of T cells confers increased pulmonary arterial hypertension and vascular remodeling. Am J Respir Crit Care Med. 2007;175(12):1280-1289. (Pubitemid 46905754)
95. Tamosiuniene R, et al. Regulatory T cells limit vascular endothelial injury and prevent pulmonary hypertension. Circ Res. 2011;109(8):867-879.
96. Bauer EM, Zheng H, Comhair S, Erzurum S, Billiar TR, Bauer PM. Complement C3 deficiency attenuates chronic hypoxia-induced pulmonary hypertension in mice. PLoS One. 2011;6(12):e28578.
97. Schober A, Zernecke A. Chemokines in vascular remodeling. Thromb Haemost. 2007;97(5):730-737. (Pubitemid 46779958)
98. Brauner EV, et al. Indoor particles affect vascular function in the aged: an air filtration-based intervention study. Am J Respir Crit Care Med. 2008;177(4):419-425. (Pubitemid 351317585)
99. Steiner MK, Syrkina OL, Kolliputi N, Mark EJ, Hales CA, Waxman AB. Interleukin-6 overexpression induces pulmonary hypertension. Circ Res. 2009;104(2):236-244.
100. Perros F, et al. Fractalkine-induced smooth muscle cell proliferation in pulmonary hypertension. Eur Respir J. 2007;29(5):937-943. (Pubitemid 46711898)
101. Courboulin A, et al. Kruppel-like Factor 5 contributes to pulmonary artery smooth muscle proliferation and resistance to apoptosis in human pulmonary arterial hypertension. Respir Res. 2011;12:128.
102. Li M, et al. Emergence of fibroblasts with a proinflammatory epigenetically altered phenotype in severe hypoxic pulmonary hypertension. J Immunol. 2011;187(5):2711-2722.
103. Vergadi E, et al. Early macrophage recruitment and alternative activation are critical for the later development of hypoxia-induced pulmonary hypertension. Circulation. 2011;123(18):1986-1995.
104. Frid MG, et al. Hypoxia-induced pulmonary vascular remodeling requires recruitment of circulating mesenchymal precursors of a monocyte/macrophage lineage. Am J Pathol. 2006;168(2):659-669. (Pubitemid 43271163)
105. Yeager ME, et al. Circulating fibrocytes are increased in children and young adults with pulmonary hypertension. Eur Respir J. 2012;39(1):104-111.
106. Perros F, et al. Pulmonary lymphoid neogenesis in idiopathic pulmonary arterial hypertension. Am J Respir Crit Care Med. 2012;185(3):311-321.
107. Dib H, et al. Targets of anti-endothelial cell antibodies in pulmonary hypertension and scleroderma. Eur Respir J. 2012;39(6):1405-1414.
108. Bonnet S, et al. The nuclear factor of activated T cells in pulmonary arterial hypertension can be therapeutically targeted. Proc Natl Acad Sci U S A. 2007;104(27):11418-11423. (Pubitemid 47175155)
109. Courboulin A, et al. Role for miR-204 in human pulmonary arterial hypertension. J Exp Med. 2011;208(3):535-548.
110. Todorovich-Hunter L, Dodo H, Ye C, McCready L, Keeley FW, Rabinovitch M. Increased pulmonary artery elastolytic activity in adult rats with monocrotaline-induced progressive hypertensive pulmonary vascular disease compared with infant rats with nonprogressive disease. Am Rev Respir Dis. 1992;146(1):213-223.
111. Ye C, Rabinovitch M. Inhibition of elastolysis by SC-37698 reduces development and progression of monocrotaline pulmonary hypertension. Am J Physiol. 1991;261(4 pt 2):H1255-H1267.
112. Maruyama K, et al. Chronic hypoxic pulmonary hypertension in rats and increased elastolytic activity. Am J Physiol. 1991;261(6 pt 2):H1716-H1726.
113. Cowan KN, Heilbut A, Humpl T, Lam C, Ito S, Rabinovitch M. Complete reversal of fatal pulmonary hypertension in rats by a serine elastase inhibitor. Nat Med. 2000;6(6):698-702. (Pubitemid 30398796)
114. McMurtry MS, et al. Gene therapy targeting survivin selectively induces pulmonary vascular apoptosis and reverses pulmonary arterial hypertension. J Clin Invest. 2005;115(6):1479-1491. (Pubitemid 40814657)
115. Kim YM, et al. Neutrophil elastase is produced by pulmonary artery smooth muscle cells and is linked to neointimal lesions. Am J Pathol. 2011;179(3):1560-1572.
116. Lawrie A, et al. Paigen diet-fed apolipoprotein E knockout mice develop severe pulmonary hypertension in an interleukin-1-dependent manner. Am J Pathol. 2011;179(4):1693-1705.
117. Yeager ME, Belchenko DD, Nguyen CM, Colvin KL, Ivy DD, Stenmark KR. Endothelin-1, the unfolded protein response, and persistent inflammation: role of pulmonary artery smooth muscle cells. Am J Respir Cell Mol Biol. 2012;46(1):14-22.
118. Bonnet S, et al. An abnormal mitochondrialhypoxia inducible factor-1alpha-Kv channel pathway disrupts oxygen sensing and triggers pulmonary arterial hypertension in fawn hooded rats: similarities to human pulmonary arterial hypertension. Circulation. 2006;113(22):2630-2641. (Pubitemid 43948012)
119. Archer SL, et al. Epigenetic attenuation of mitochondrial superoxide dismutase 2 in pulmonary arterial hypertension: a basis for excessive cell proliferation and a new therapeutic target. Circulation. 2010;121(24):2661-2671.
120. Fantozzi I, et al. Bone morphogenetic protein-2 upregulates expression and function of voltagegated K+ channels in human pulmonary artery smooth muscle cells. Am J Physiol Lung Cell Mol Physiol. 2006;291(5):L993-L1004. (Pubitemid 44772062)
121. Cogolludo A, et al. Serotonin inhibits voltagegated K+ currents in pulmonary artery smooth muscle cells: role of 5-HT2A receptors, caveolin-1, and KV1.5 channel internalization. Circ Res. 2006;98(7):931-938.
122. McMurtry MS, et al. Dichloroacetate prevents and reverses pulmonary hypertension by inducing pulmonary artery smooth muscle cell apoptosis. Circ Res. 2004;95(8):830-840. (Pubitemid 39390586)
123. Sutendra G, et al. The role of Nogo and the mitochondria-endoplasmic reticulum unit in pulmonary hypertension. Sci Transl Med. 2011;3(88):88ra55.
124. Sutendra G, et al. Fatty acid oxidation and malonyl-CoA decarboxylase in the vascular remodeling of pulmonary hypertension. Sci Transl Med. 2010;2(44):44ra58.
125. Coller HA. Cell biology. The essence of quiescence. Science. 2011;334:1074-1075.
126. Lee SJ, et al. Autophagic protein LC3B confers resistance against hypoxia-induced pulmonary hypertension. Am J Respir Crit Care Med. 2011;183(5):649-658.
127. Hickey MM, et al. The von Hippel-Lindau Chuvash mutation promotes pulmonary hypertension and fibrosis in mice. J Clin Invest. 2010;120(3):827-839.
128. Abe K, et al. Long-term treatment with a Rho-kinase inhibitor improves monocrotaline-induced fatal pulmonary hypertension in rats. Circ Res. 2004;94(3):385-393. (Pubitemid 38240731)
129. Zhang S, et al. Pulmonary artery smooth muscle cells from normal subjects and IPAH patients show divergent cAMP-mediated effects on TRPC expression and capacitative Ca2+ entry. Am J Physiol Lung Cell Mol Physiol. 2007;292(5):L1202-L1210. (Pubitemid 47084864)
130. Austin ED, et al. Alterations in estrogen metabolism: Implications for higher penetrance of FPAH in females. Eur Respir J. 2009;34(5):1093-1099.
131. Dempsie Y, et al. Development of pulmonary arterial hypertension in mice over-expressing S100A4/Mts1 is specific to females. Respir Res. 2011;12:159.
132. Umar S, et al. Estrogen rescues preexisting severe pulmonary hypertension in rats. Am J Respir Crit Care Med. 2011;184(6):715-723.
133. Lahm T, et al. 17β-Estradiol attenuates hypoxic pulmonary hypertension via estrogen receptor-mediated effects. Am J Respir Crit Care Med. 2012;185(9):965-980.
134. Zamanian RT, et al. Insulin resistance in pulmonary arterial hypertension. Eur Respir J. 2009;33(2):318-324.
135. Kumar PA, et al. Distal airway stem cells yield alveoli in vitro and during lung regeneration following H1N1 influenza infection. Cell. 2011;147(3):525-538.
136. Ding BS, et al. Endothelial-derived angiocrine signals induce and sustain regenerative lung alveolarization. Cell. 2011;147(3):539-553.
137. Zhao YD, Courtman DW, Deng Y, Kugathasan L, Zhang Q, Stewart DJ. Rescue of monocrotalineinduced pulmonary arterial hypertension using bone marrow-derived endothelial-like progenitor cells: efficacy of combined cell and eNOS gene therapy in established disease. Circ Res. 2005;96(4):442-450. (Pubitemid 40354538)
138. Deng W, St Hilaire RC, Chattergoon NN, Jeter JR Jr, Kadowitz PJ. Inhibition of vascular smooth muscle cell proliferation in vitro by genetically engineered marrow stromal cells secreting calcitonin generelated peptide. Life Sci. 2006;78(16):1830-1838.
139. Baber SR, et al. Intratracheal mesenchymal stem cell administration attenuates monocrotalineinduced pulmonary hypertension and endothelial dysfunction. Am J Physiol Heart Circ Physiol. 2007;292(2):H1120-H1128.
140. Weinberg CE, et al. Extraction of pulmonary vascular compliance, pulmonary vascular resistance, and right ventricular work from single-pressure and Doppler flow measurements in children with pulmonary hypertension: a new method for evaluating reactivity: in vitro and clinical studies. Circulation. 2004;110(17):2609-2617. (Pubitemid 39453010)
141. Mahmud M, Champion HC. Right ventricular failure complicating heart failure: pathophysiology, significance, and management strategies. Curr Cardiol Rep. 2007;9(3):200-208. (Pubitemid 46784415)
142. Vanderpool RR, El-Bizri N, Rabinovitch M, Chesler NC. Patchy deletion of Bmpr1a potentiates proximal pulmonary artery remodeling in mice exposed to chronic hypoxia [published online ahead of print February 8, 2012]. Biomech Model Mechanobiol. doi:10.1007/s10237-012-0379-6.
143. Chung L, et al. Characterization of connective tissue disease-associated pulmonary arterial hypertension from REVEAL: identifying systemic sclerosis as a unique phenotype. Chest. 2010;138(6):1383-1394.
144. Strowig T, Henao-Mejia J, Elinav E, Flavell R. Inflammasomes in health and disease. Nature. 2012; 481(7381):278-286.
145. Ikonomou L, et al. Programmatic change: lung disease research in the era of induced pluripotency. Am J Physiol Lung Cell Mol Physiol. 2011;301(6):L830-L835.